黑色素瘤FDG PET/CT分期与疗效评估的实践要点
本文讨论黑色素瘤患者FDG PET/CT分期与复发检测中,不同器官或部位以及皮肤与脉络膜来源之间敏感度和特异度的差异及其对临床决策的影响。文章还总结免疫治疗后可能出现的假阳性表现,以帮助核医学科医生在疗效评估中避免误判。
要点
- FDG PET/CT对III和IV期黑色素瘤分期及复发检测具高敏感度和特异度,但结果因部位和来源而异。
- 皮肤与脉络膜来源黑色素瘤的器官或部位相关敏感度和特异度差异影响临床决策。
- 免疫治疗后可能出现治疗相关假阳性,识别这些表现对准确评估疗效至关重要。
核心结论
- FDG PET/CT对III和IV期黑色素瘤分期及复发检测具高敏感度和特异度,但总体结果因身体部位及皮肤或脉络膜来源而异。
- 免疫治疗后出现的治疗相关潜在假阳性表现是准确评估疗效时必须掌握的知识。
研究设计与样本
- 本文为综述,讨论黑色素瘤患者FDG PET/CT判读中的实践考虑,未报告系统检索范围。
主要发现
- FDG PET/CT对III和IV期黑色素瘤分期及复发检测具高敏感度和特异度。
- 敏感度和特异度因身体部位以及皮肤或脉络膜来源不同而存在差异。
- 免疫治疗后出现治疗相关潜在假阳性表现,可影响疗效评估。
临床怎么用
- 核医学科医生判读黑色素瘤FDG PET/CT时应考虑部位及皮肤或脉络膜来源对敏感度和特异度的影响。
- 对接受免疫治疗的患者,应识别治疗相关潜在假阳性表现,避免对FDG PET/CT图像的误判。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
While FDG PET/CT bears a high sensitivity and specificity for the staging of stage III and IV melanoma as well as for the purpose of melanoma recurrence detection, overall results tend to vary from one part of the body to another as well as for melanoma from cutaneous or choroidal origin. In this paper, organ or site-related differences in sensitivity and specificity in melanoma patients, both from cutaneous and choroidal origin, as well as their impact on clinical decision making are discussed. Furthermore, with the advent of immunotherapy for the treatment of malignant melanoma, post-treatment related potential false positive findings have emerged, the knowledge of which is essential for accurate treatment response assessment. These post-treatment related potential false positive findings are summarized in this paper so as to help the nuclear medicine physician in avoiding erroneous interpretation of acquired FDG PET/CT images in melanoma patients receiving immuntherapy.
引用
- Van de Wiele C, Juanito G, Vander BK, et al. Practical Considerations When Interpreting FDG PET/CT Imaging for Staging and Treatment Response Assessment in Melanoma Patients. Semin Nucl Med. 2021. PMID: 34246450. doi:10.1053/j.semnuclmed.2021.06.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。